Start Your Search
Best abstracts selected from submissions 5 (ID 6)
- Event: ACLC 2018
- Type: Oral Session
- Presentations: 1
- Coordinates: 11/09/2018, 16:20 - 17:00, Crystal Ballroom 1
OA09 - Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer (ID 178)
16:20 - 17:00 | Author(s): R. Doebele
Patients (pts) with ROS1+ advanced NSCLC can be effectively treated with ROS1 tyrosine kinase inhibitors (TKIs). However, acquired resistance inevitably develops, resulting in disease relapse. Repotrectinib is a potent next-generation ROS1/TRK/ALK TKI, which inhibits ROS1 with a >90-fold greater potency (IC50 <0.2 nM) than crizotinib. Preclinical studies demonstrate robust activity of repotrectinib against all known clinical ROS1 resistance mutations, including ROS1 G2032R resistance solvent-front mutation.
In this phase I study (NCT03093116), eligible adult pts with TKI-na
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.